Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 5, 2008
Event: Entry into a definitive material agreement involving the adoption of a shareholder rights plan (poison pill).
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure changes.
Material Changes
The Board of Directors adopted a Shareholder Rights Agreement on February 5, 2008. Key terms include:
- Dividend Declaration: One Preferred Stock Purchase Right (Right) per outstanding share of Common Stock to shareholders of record as of February 6, 2008.
- Exercise Price: $44.00 per Unit (one ten-thousandth of a share of Series A Junior Participating Cumulative Preferred Stock).
- Trigger Threshold: Rights become exercisable if an "Acquiring Person" acquires 20% or more of outstanding Common Stock.
- Flip-In Provision: Upon a stock acquisition, holders (excluding the Acquiring Person) may exchange Rights for Common Stock with a market value of two times the exercise price.
- Flip-Over Provision: In the event of a merger or sale of assets, holders may exchange Rights for stock of the acquiring company with a market value of two times the exercise price.
- Redemption: The Board may redeem Rights at $0.01 per Right until an Acquiring Person emerges.
- Expiration: Rights expire on February 6, 2018, unless redeemed or exchanged earlier.
Guidance, Outlook, and Risks
Management Commentary: The filing describes the mechanics of the rights plan but does not provide forward-looking financial guidance or operational outlook.
Risks and Contingencies:
- Tax Implications: While the distribution is not taxable, stockholders may recognize taxable income if Rights become exercisable for Units, other securities, or consideration.
- Shareholder Rights: Until exercised, Rights holders have no voting or dividend rights beyond those of existing stockholders.
- Acquisition Deterrence: The plan is designed to discourage unsolicited takeover attempts by diluting the value of shares acquired by an Acquiring Person.
Investor Verification Checklist
- Verify the current trading price of Common Stock relative to the $44.00 exercise price per Unit.
- Confirm the Record Date (February 6, 2008) to determine eligibility for the Rights distribution.
- Review the attached Shareholder Rights Agreement (Exhibit 4.1) for specific adjustment formulas and exceptions.
- Check for any existing shareholders who may qualify as "Grandfathered Persons" (owning 20%+ as of the Record Date).
- Monitor for any press releases regarding the redemption of Rights or changes to the 20% threshold.